Asciminib Monotherapy, With Dose Escalation, for 2nd and 1st Line Chronic Myelogenous Leukemia (NCT05384587)
A Phase II Multicenter, Open-label, Single-arm Dose Escalation Study of Asciminib Monotherapy in 2nd and 1st Line Chronic Phase - Chronic Myelogenous Leukemia (ASC2ESCALATE)
🩺 Plain-English Summary (8th-Grade Level)
This will be a multicenter Phase II open-label study of asciminib in CML-CP patients who have been previously treated with one prior ATP- binding site TKI with discontinuation due to treatment failure, warning or intolerance. (2L patient cohort). In addition, newly diagnosed CML-CP patients who may have received up to 4 weeks of prior TKI are included in a separate 1L patient cohort.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham — Birmingham, Alabama
Age range: 18 Years to 100 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (80 Sites)
Showing the first 25 of 80 sites.
- University of Alabama at Birmingham — Birmingham, Alabama
- Alaska Oncology and Hematology — Anchorage, Alaska
- City of Hope Phoenix — Scottsdale, Arizona
- USO Arizona Oncology — Tucson, Arizona
- Onco Inst of Hope and Innovation — Cerritos, California
- City of Hope National Medical — Duarte, California
- UCSF Fresno Internal Medicine — Fresno, California
- Virginia K Crosson Cancer Center — Fullerton, California
- UCLA — Los Angeles, California
- Alta Bates Summit Medical Center — Oakland, California
- Lundquist Inst BioMed at Harbor — Torrance, California
- Rocky Mountain Cancer Centers — Boulder, Colorado
- Yale University School Of Medicine — New Haven, Connecticut
- The Stamford Hospital — Stamford, Connecticut
- Florida Cancer Specialists — Fort Myers, Florida
- Baptist MD Anderson Cancer Center — Jacksonville, Florida
- Florida Cancer Specialists-North — St. Petersburg, Florida
- Florida Cancer Specialists East — Stuart, Florida
- City Of Hope Atlanta — Atlanta, Georgia
- Emory University School of Medicine Winship Cancer Institute — Atlanta, Georgia
- Augusta University Georgia — Augusta, Georgia
- Northwest Georgia Oncology Center — Marietta, Georgia
- Franciscan Health Indianapolis — Indianapolis, Indiana
- Investigative Clinicl Rsrch of Indi — Indianapolis, Indiana
- Holden Comp Can Cent Quad Cities U — Iowa City, Iowa
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Myelogenous Leukemia - Chronic Phase
Explore by condition: All Chronic Myelogenous Leukemia - Chronic Phase clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.